235 related articles for article (PubMed ID: 34078651)
1. Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.
Virtakoivu R; Rannikko JH; Viitala M; Vaura F; Takeda A; Lönnberg T; Koivunen J; Jaakkola P; Pasanen A; Shetty S; de Jonge MJA; Robbrecht D; Ma YT; Skyttä T; Minchom A; Jalkanen S; Karvonen MK; Mandelin J; Bono P; Hollmén M
Clin Cancer Res; 2021 Aug; 27(15):4205-4220. PubMed ID: 34078651
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers.
Hollmén M; Maksimow M; Rannikko JH; Karvonen MK; Vainio M; Jalkanen S; Jalkanen M; Mandelin J
Mol Cancer Ther; 2022 Jul; 21(7):1207-1218. PubMed ID: 35500016
[TBL] [Abstract][Full Text] [Related]
3. New tools to prevent cancer growth and spread: a 'Clever' approach.
Hollmén M; Figueiredo CR; Jalkanen S
Br J Cancer; 2020 Aug; 123(4):501-509. PubMed ID: 32595212
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8
Viitala M; Virtakoivu R; Tadayon S; Rannikko J; Jalkanen S; Hollmén M
Clin Cancer Res; 2019 Jun; 25(11):3289-3303. PubMed ID: 30755440
[TBL] [Abstract][Full Text] [Related]
5. Clever-1/stabilin-1 controls cancer growth and metastasis.
Karikoski M; Marttila-Ichihara F; Elima K; Rantakari P; Hollmén M; Kelkka T; Gerke H; Huovinen V; Irjala H; Holmdahl R; Salmi M; Jalkanen S
Clin Cancer Res; 2014 Dec; 20(24):6452-64. PubMed ID: 25320356
[TBL] [Abstract][Full Text] [Related]
6. Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Rannikko JH; Verlingue L; de Miguel M; Pasanen A; Robbrecht D; Skytta T; Iivanainen S; Shetty S; Ma YT; Graham DM; Arora SP; Jaakkola P; Yap C; Xiang Y; Mandelin J; Karvonen MK; Jalkanen J; Karaman S; Koivunen JP; Minchom A; Hollmén M; Bono P
Cell Rep Med; 2023 Dec; 4(12):101307. PubMed ID: 38056464
[TBL] [Abstract][Full Text] [Related]
7. Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages.
Palani S; Maksimow M; Miiluniemi M; Auvinen K; Jalkanen S; Salmi M
Eur J Immunol; 2011 Jul; 41(7):2052-63. PubMed ID: 21480214
[TBL] [Abstract][Full Text] [Related]
8. Clever-1 positive macrophages in breast cancer.
Mutka M; Virtakoivu R; Joensuu K; Hollmén M; Heikkilä P
Breast Cancer Res Treat; 2022 Oct; 195(3):237-248. PubMed ID: 35917053
[TBL] [Abstract][Full Text] [Related]
9. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of
Moisio O; Virta J; Yatkin E; Liljenbäck H; Palani S; Viitanen R; Miner MWG; Oikonen V; Tolvanen T; Vugts DJ; Taimen P; Li XG; Hollmén M; Jalkanen S; Roivainen A
J Nucl Med; 2023 Apr; 64(4):555-560. PubMed ID: 36302655
[TBL] [Abstract][Full Text] [Related]
11. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
12. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
13. Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments.
Rannikko JH; Bono P; Hynninen J; Hollmén M
Cancer Immunol Res; 2024 Jan; 12(1):48-59. PubMed ID: 37922365
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of Nitric Oxide Collaborated with Radiotherapy to Promote Anti-Tumor Immune Response via Inducing CD8+ T Cell Infiltration.
Xu J; Luo Y; Yuan C; Han L; Wu Q; Xu L; Gao Y; Sun Y; Ma S; Tang G; Li S; Sun W; Gong Y; Xie C
Int J Biol Sci; 2020; 16(9):1563-1574. PubMed ID: 32226302
[TBL] [Abstract][Full Text] [Related]
16. Lymphatic expression of CLEVER-1 in breast cancer and its relationship with lymph node metastasis.
Ammar A; Mohammed RA; Salmi M; Pepper M; Paish EC; Ellis IO; Martin SG
Anal Cell Pathol (Amst); 2011; 34(1-2):67-78. PubMed ID: 21483103
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.
Yamaguchi Y; Gibson J; Ou K; Lopez LS; Ng RH; Leggett N; Jonsson VD; Zarif JC; Lee PP; Wang X; Martinez C; Dorff TB; Forman SJ; Priceman SJ
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738799
[TBL] [Abstract][Full Text] [Related]
18. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
19. Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization.
Jagodinsky JC; Bates AM; Clark PA; Sriramaneni RN; Havighurst TC; Chakravarty I; Nystuen EJ; Kim K; Sondel PM; Jin WJ; Morris ZS
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192087
[TBL] [Abstract][Full Text] [Related]
20. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
Semmrich M; Marchand JB; Fend L; Rehn M; Remy C; Holmkvist P; Silvestre N; Svensson C; Kleinpeter P; Deforges J; Junghus F; Cleary KL; Bodén M; Mårtensson L; Foloppe J; Teige I; Quéméneur E; Frendéus B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
